Kolexia
Deutsch Eric
Oncologie radiothérapie
Gustave-Roussy
Villejuif, France
543 Activités
9 K Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinomes Tumeurs du col de l'utérus Carcinome épidermoïde Tumeurs de la tête et du cou Métastase tumorale Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Carcinome épidermoïde de la tête et du cou

Industries

Boehringer Ingelheim
5 collaboration(s)
Dernière en 2023
Roche
3 collaboration(s)
Dernière en 2021
Merck
2 collaboration(s)
Dernière en 2020
Debiopharm
1 collaboration(s)
Dernière en 2023

Dernières activités

PRAAR1: An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)
Essai Clinique (Gustave-Roussy)   07 février 2024
Clinical research for global needs of radiation oncology.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   28 décembre 2023
Correction: Reproducible big data science: A case study in continuous FAIRness.
PloS one   21 novembre 2023
KRAS inhibition using MRTX1257: a novel radio-sensitizing partner.
Journal of translational medicine   31 octobre 2023
Integrating F-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors.
Cancers   27 octobre 2023
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
2257P Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
2252P KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.: Blue Sky Radiomics: an Observational Study on Computed Tomography as an Image-based Predictive Marker of Response to Chemoradiation Followed by Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer (NSCLC).
Essai Clinique (IRCCS Policlinico S. Matteo)   26 septembre 2023
P11.79.B MULTICENTRE MULTI-COMPONENT DATA COLLECTION TO DEFINE NEW PREDICTORS OF RELAPSE IN HIGH GRADE GLIOMA
Abstracts from the 18th Meeting of the European Association of Neuro-Oncology   08 septembre 2023